| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA731: Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal) |
|
Medicine details |
|
| Medicine name | vericiguat (Verquvo®) |
| Formulation | 2.5 mg, 5 mg, 10 mg film-coated tablet |
| Reference number | 3365 |
| Indication | Treatment of symptomatic chronic heart failure in adults with reduced ejection fraction who are stabilised after a recent decompensation event requiring IV therapy |
| Company | Bayer Healthcare Pharmaceuticals |
| BNF chapter | Cardiovascular system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 24/06/2021 |
| NICE guidance | |